Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xuan Pei
Observed names:
Pei, Xuan,
X. Pei
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Memorial Sloan Kettering Cancer Center,
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Minhang District Central Hospital,
ORCID
show all 6
ORCID:
0000-0002-4654-2222
Observed ORCID:
0000-0002-4654-2222
OpenAlex ID:
A5001773311
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer
2018
·
Wei Jiang
, Tiancong He
, et al.
·
Journal of Hematology & Oncology
·
123
PDF
Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth
2022
·
Xuan Pei
, Kai-Yue Li
, et al.
·
Science China Life Sciences
·
82
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix
2021
·
Xuan Pei
, Libing Xiang
, et al.
·
Gynecologic Oncology
·
54
PDF
Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients
2020
·
Yutuan Wu
, Shuang Ye
, et al.
·
BMC Cancer
·
53
PDF
Mutational analysis ofKRASand its clinical implications in cervical cancer patients
2018
·
Wei Jiang
, Libing Xiang
, et al.
·
Journal of Gynecologic Oncology
·
50
PDF
Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix
2017
·
Xuan Pei
, Libing Xiang
, et al.
·
Gynecologic Oncology
·
50
ERBB2 mutation: A promising target in non-squamous cervical cancer
2017
·
Libing Xiang
, Wei Jiang
, et al.
·
Gynecologic Oncology
·
46
Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma
2019
·
Huijuan Yang
, Shuang Ye
, et al.
·
International Journal of Cancer
·
36
Mutational analysis of KRAS and its clinical implications in cervical cancer patients
2017
·
Wei Jiang
, Libing Xiang
, et al.
·
Journal of Gynecologic Oncology
·
13
Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III–IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study
2024
·
Lina Yin
, Wei Jiang
, et al.
·
BMC Medicine
·
12
PDF
Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival
2023
·
Shuang Ye
, Shuling Zhou
, et al.
·
Annals of Medicine
·
10
PDF
A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer
2023
·
Wei Jiang
, Xueyan Ouyang
, et al.
·
International Journal of Molecular Sciences
·
8
PDF
Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1)
2018
·
Wei Jiang
, Shuang Ye
, et al.
·
Journal of Ovarian Research
·
7
PDF
Efficacy and safety of distamab vedotin combined with carboplatin and bevacizumab for HER2-expressing platinum-sensitive ovarian cancer with prior PARPi treatment.
2025
·
Huijuan Yang
, Wei Jiang
, et al.
·
Journal of Clinical Oncology
·
2
PDF
EV344/#770 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
2024
·
Shuang Ye
, Yi Fu
, et al.
·
International Journal of Gynecological Cancer
·
2
PDF
Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery
2021
·
Wei Chen
, Shuang Ye
, et al.
·
Journal of Ovarian Research
·
2
PDF
Targeting lactate with a GLUT1 inhibitor reverses PARP inhibitor resistance in ovarian cancer
2025
·
Shuqi Nie
, Congli Pu
, et al.
·
Acta Biochimica et Biophysica Sinica
·
1
Surufatinib Combined With Toripalimab For The Treatment Of Recurrent Ovarian Clear Cell Carcinoma: Update Of A Prospective Single Center, Single-Arm Phase II Clinical Trial
2025
·
Shuang Ye
, Yi Fu
, et al.
·
International Journal of Gynecological Cancer
·
1
PDF
Characterization of the single-cell adaptive immune landscape and its clinical implications in high-grade serous ovarian cancer
2026
·
Congli Pu
, Teng Li
, et al.
·
Journal of Ovarian Research
Debulking Surgery of Retroperitoneal Lymph Node Metastasis in Primary Cytoreductive Surgery for Advanced Ovarian Cancer
2026
·
Huijuan Yang
, Boer Shan
, et al.
·
International Journal of Gynecological Cancer
Updated efficacy of dalpiciclib and nonsteroidal aromatase inhibitors (NSAIs) in estrogen receptor–positive (ER+) recurrent/metastatic (R/M) ovarian cancer and uterine neoplasms.
2026
·
Huijuan Yang
, Wei Jiang
, et al.
·
Journal of Clinical Oncology
Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial.
2026
·
Huijuan Yang
, Yi Fu
, et al.
·
Journal of Clinical Oncology
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA
2025
·
Yixiu Long
, Xuan Pei
, et al.
·
Human Cell
PDF
Identification of Immune Subtypes and a Prognostic Model for Lung Oligometastases in Cervical Cancer
2025
·
Huijuan Yang
, Congli Pu
, et al.
·
SSRN Electronic Journal
SF049/#1119 Sentinel lymph node mapping with indocyanine green (ICG) using fluorescent imaging device in malignant tumors of the vulva
2024
·
Anran Cheng
, Xuan Pei
, et al.
·
International Journal of Gynecological Cancer
PDF
Show more works
View as search
Works count:
33
Citation count:
549
H-index:
10
I10-index:
11
Year
Topic
Type